Emirates Biotech's new leadership team

Emirates Biotech has formed a new leadership team following the appointment of Marc Verbruggen as CEO last month.

Joining him are François de Bie as chief commercial officer, Aman Kulshrestha as chief technology officer, and Margrete L. Wie as head of finance. This team, based in Dubai, brings exceptional expertise and vision to propel Emirates Biotech towards becoming a leader in the PLA (Polylactic Acid) biopolymer industry.

Marc Verbruggen, a prominent figure in the bioplastics sector, previously served as CEO of NatureWorks. Under his leadership, NatureWorks expanded its manufacturing capacity and built a strong global customer base. Marc’s strategic direction will be crucial for Emirates Biotech in navigating the dynamic biopolymer market.

Growth in the Middle East

François de Bie, with his extensive background in business development and marketing within the plastics industry, formerly served as senior marketing director at TotalEnergies Corbion and president of European Bioplastics. His expertise will drive Emirates Biotech’s regional sales and marketing strategy.

Aman Kulshrestha, an expert with over 12 years of experience in biopolymers, has held positions at NatureWorks and Sulzer, specializing in production, biopolymer applications, and recycling technologies. She will oversee Emirates Biotech’s technological advancements, ensuring the production of high-quality PLA biopolymers.

Margrete L. Wie, appointed as head of finance, will manage Emirates Biotech's financial operations. She has a strong background in financial and strategic management within complex technology industries, both in start-up and mature business environments.

Emirates Biotech has recently commenced operations, focusing on the production and marketing of PLA biopolymers across the Middle East, Africa, and India. These biopolymers are renewable, recyclable, biodegradable, and support the goals of a circular economy, offering a sustainable alternative to traditional fossil fuel-based plastics.